paul fonteyne
TRANSCRIPT
Pharmaceutical Industryand Boehringer Ingelheim
Paul FonteyneExecutive Vice President
Head of Marketing & Sales, Prescription Medicines
Pharmaceutical Industry Leader in Fairfield County
Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential 2
Ridgefield, Connecticut
Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential 3
Background
• Founded in 1885 in Ingelheim, Germany
• World’s largest family-owned pharmaceutical company
• Operates worldwide - 156 affiliated companies in over 60 countries
• Focus: Human Pharmaceuticals (95%) and Animal Health
• Products in a variety of therapeutic areas- Cardiovascular, Respiratory, CNS, Virology, Oncology,
Immunology, Urology, Rheumatology, GI/Metabolic
• Research focused- Medicines for those diseases where genuine
therapeutic innovation can be demonstrated.
Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential 4
Worldwide - 2004
•Total Net Sales $ 10.2 Billion-Human Pharma 96%-Animal Health 4%
•Total Employees nearly 36,000
•R&D+C Expenditures $ 1.23 Billion
Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential 5
Top 20 Corporations 2004Global Pharma Market
40
35
30
25
20
15
10
5
Source: IMS Health, IMS Health / MAT Q4 2004
in EUR billion
Pfize
r
Glaxos
mith
klin
e
Sanofi
-Ave
ntis
Johnso
n &
Johnso
n
Merck
& C
o
Novar
tis
Astra
zenec
a
Roche
Bristo
l-Mye
rs
SQB.W
yeth
Abbott
Lilly
Amgen
Take
da
Boehrin
ger
Ingelh
eimSch
erin
g
PloughBay
er
Yam
anou
chi-
Fujis
awaEisa
i
Scher
ing A
G
37.8
23.4
19.518.3 17.8
16.3 15.9
12.411.2 10.4 10.3 9.3
7.9 6.8 6.14.9 4.5 3.9 3.7 3.4
Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential 6
Top 20 Corporations ranked by Growth
30
25
20
15
10
5
-5
-10
-15
-20
Boehringer Ingelheim Growth Rate above Top 20 Corporations (+8.2%)
MAT to Q4 2004 in Constant Euro
in %
Amgen
Boehrin
ger
Ingelh
eimRoche
Abbott
Astra
zenec
a
Sanofi
-Ave
ntis
Wye
thEsa
i
Johnso
n &
Johnso
n
Novar
tis
Scher
ing A
GLil
ly
Take
daPfi
zer
Merck
& C
o
Glaxos
mith
kline
Yam
anou
chi-
Fujis
awa
Bayer
Bristo
l-Mye
rs
SQB.
Scher
ing
Plough
25.5
14.3
10.2 9.4 9.2 9.0 9.0 8.4 8.0 7.3 6.4 6.1 5.84.7 3.5
1.8
-1.2-3.9
-13.2
1.3
Source: IMS Health, IMS Health / MAT Q4 2004
Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential 7
Prescription MedicinesOur Six Highlights
flomax®
mobic®
micardis®
viramune®
spiriva®
mirapex®
Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential 8
Ridgefield Campus Projects
• Lead Discovery Technologies Building dedicated in 2001
• Kilo Lab• Completed in 2005, produces drug substances up to 5
kg quantities for research purposes.
• On-site Child Care Center; September 2006• 19,000 sq ft stand alone building with a capacity for
256 infants, toddlers and preschoolers.
• Physical Sciences building; March 2007• 86,000 sq ft building to accommodate relocation of
our cardiovascular diseases research program from Germany.
• 3 floors, 119 work stations for scientists and management.
Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential 9
BI Cares Foundation
The Foundation’s mission is to improve lives through innovative philanthropic contributions and donations of healthcare products and resources.
• BI Cares Foundation Patient Assistance Plan (170,000 patients expected to be enrolled in 2005)
• Hurricane Rita and Katrina assistance
• Product Donation Program ($160M in product donation anticipated in 2005)
• Cash contributions in 2004 - $1.9M
Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential 10
Community Involvement - CT• Lung Health Screening Program• United Way of Northern Fairfield County• Regional Hospice of Western Connecticut• American Red Cross• Connecticut PBS – Family Science Expo• Abilities Beyond Disabilities (DATAHR)• Connecticut United for Research Excellence• Ives Center for the Arts• Girl Scout Council of SW Connecticut• Regional YMCA Center for Arts & Humanities• Special Olympics – Connecticut• Western Connecticut State University
Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential 11
Pharmaceutical Industry Challenges - Government• Prescription drug importation
• AKA price controls
• Promotion restrictions
• Lower market penetration of new products
• Increased costs of doing business• Energy, taxes, fees, liability
Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential 12
• Continued innovation
• Continued ability to fund R&D• Cost of and time to develop new products
• Attracting talented, highly educated workforce
• Continue to effectively and efficiently serve a diverse and changing marketplace• Physicians, patients, institutions, payors
Pharmaceutical Industry Challenges - Industry
Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential 13
Summary
• BI is a growing, innovative pharmaceutical company and employer in Fairfield County
• BI is committed to delivering value to patients and to the healthcare community
• Challenges to the healthcare marketplace and pharmaceutical industry are significant
Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential 14
Web information
• http://www.boehringer-ingelheim.com Worldwide web
• http://us.boehringer-ingelheim.com US company web
• https://www.pparx.org/Intro.php Partnership for Prescription Assistance
• http://us.boehringer-ingelheim.com/about/philanthropy/Patient_Assistance_Program.html BI Cares Foundation Patient Assistance web
Pharmaceutical Industryand Boehringer Ingelheim
Paul FonteyneExecutive Vice President
Head of Marketing & Sales, Prescription Medicines
Pharmaceutical Industry Leader in Fairfield County